United States was Bristol Myers Squibb’s largest region in fiscal 2025, bringing in $33.28B of $48.19B (69%).
| Geography | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $31.50B | $31.21B | $34.11B | $33.28B | |||||||||||||
| International | $13.83B | $13.10B | $13.20B | $13.83B | |||||||||||||
| Europe | — | — | — | — | |||||||||||||
| European Union | — | — | — | — | |||||||||||||
| Rest Of World | — | — | — | — | |||||||||||||
| Japan Asia Pacific & Canada | — | — | — | — | |||||||||||||
| Latin America Middle East & Africa | — | — | — | — | |||||||||||||
| Emerging Markets | — | — | — | — | |||||||||||||
| Other | $834.00M | $699.00M | $996.00M | $1.09B | |||||||||||||
| Other Region | — | — | — | — | |||||||||||||
| Total | $46.16B | $45.01B | $48.30B | $48.19B |
Bristol Myers Squibb brought in $48.19B from its three regions in fiscal 2025, the year ended December 31, 2025. That was down 0.2% from $48.30B in fiscal 2024. United States was the largest at $33.28B (69.1%), ahead of International at $13.83B (28.7%) and Other at $1.09B (2.3%).
Compared with fiscal 2024, Other grew fastest, up 9.1% to $1.09B, while United States fell the most, down 2.4% to $33.28B. From fiscal 2022 to 2025, combined revenue from these regions grew from $46.16B to $48.19B, a compound annual growth rate of 1.4%. United States' share of the total rose from 68.2% to 69.1%.
Alliance Partners was Bristol Myers Squibb’s largest revenue line in fiscal 2012, bringing in $9.87B of $17.62B (56%).
| <link:loc xlink:href="bmy-20141231.xsd#bmy_AlliancesAndCollaborationCompaniesAxis" xlink:label="loc_bmy_AlliancesAndCollaborationCompaniesAxis_5B11C7074433AAB7618B76154276B522" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmy_AlliancesAndCollaborationCompaniesAxis_5B11C7074433AAB7618B76154276B522" xlink:to="lab_bmy_AlliancesAndCollaborationCompaniesAxis_5B11C7074433AAB7618B76154276B522" xlink:type="arc" /> <link:label id="lab_bmy_AllianceAndCollaborationCompaniesDomain_CB01DA2AE22BF8C995D1761542764A54_terseLabel_en-US" xlink:label="lab_bmy_AllianceAndCollaborationCompaniesDomain_CB01DA2AE22BF8C995D1761542764A54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alliance Companies [Domain] | FY 2012 |
|---|---|
| Alliance Partners | $9.87B |
| Otsuka | $3.73B |
| Sanofi | $3.05B |
| Astrazeneca | $972.00M |
| Pfizer | $2.00M |
| Total | $17.62B |
Bristol Myers Squibb brought in $17.62B from its five revenue lines in fiscal 2012, the year ended December 31, 2012. Alliance Partners was the largest at $9.87B (56.0%), ahead of Otsuka at $3.73B (21.1%) and Sanofi at $3.05B (17.3%). The other two revenue lines brought in $974.00M combined.
Plavix* was Bristol Myers Squibb’s largest revenue line in fiscal 2008, bringing in $5.60B of $17.72B (32%).
| Concentration Risk by Benchmark | FY 2008 |
|---|---|
| Plavix* | $5.60B |
| Sales Revenue Segment Mature Products & All Other | $4.09B |
| Abilify* | $2.15B |
| Reyataz | $1.29B |
| Avapro*/Avalide* | $1.29B |
| Sustiva Franchise (Total Revenue) | $1.15B |
| Erbitux* | $749.00M |
| Baraclude | $541.00M |
| Orencia | $441.00M |
| Sprycel | $310.00M |
| Ixempra | $101.00M |
| Total | $17.72B |
Bristol Myers Squibb brought in $17.72B from its 11 revenue lines in fiscal 2008, the year ended December 31, 2008. Plavix* was the largest at $5.60B (31.6%), ahead of Sales Revenue Segment Mature Products & All Other at $4.09B (23.1%) and Abilify* at $2.15B (12.2%). The other eight revenue lines brought in $5.87B combined.
Bristol Myers Squibb (BMY) reports its revenue by geography, by <link:loc xlink:href="bmy-20141231.xsd#bmy_alliancesandcollaborationcompaniesaxis" xlink:label="loc_bmy_alliancesandcollaborationcompaniesaxis_5b11c7074433aab7618b76154276b522" xlink:type="locator" /> <link:labelarc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmy_alliancesandcollaborationcompaniesaxis_5b11c7074433aab7618b76154276b522" xlink:to="lab_bmy_alliancesandcollaborationcompaniesaxis_5b11c7074433aab7618b76154276b522" xlink:type="arc" /> <link:label id="lab_bmy_allianceandcollaborationcompaniesdomain_cb01da2ae22bf8c995d1761542764a54_terselabel_en-us" xlink:label="lab_bmy_allianceandcollaborationcompaniesdomain_cb01da2ae22bf8c995d1761542764a54" xlink:role="http://www.xbrl.org/2003/role/terselabel" xlink:type="resource" xml:lang="en-us">alliance companies [domain] and by concentration risk by benchmark. In fiscal 2025, United States was its largest region, bringing in $33.28B (69.1% of the total), followed by International at $13.83B (28.7%).
United States was Bristol Myers Squibb's largest region in fiscal 2025, bringing in $33.28B, or 69.1% of the $48.19B total across its three regions.
Alliance Partners was Bristol Myers Squibb's largest revenue line in fiscal 2012, bringing in $9.87B, or 56.0% of the $17.62B total across its five revenue lines.
Among Bristol Myers Squibb's regions that make up at least 2% of revenue, Other grew fastest in fiscal 2025, up 9.1% from $996.00M to $1.09B.
Every figure comes from Bristol Myers Squibb's annual financial filings, as reported. Each line keeps the name Bristol Myers Squibb gives it, and years follow its fiscal calendar.
Bristol Myers Squibb's revenue by geography goes back to fiscal 2009, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.